针对霍奇金淋巴瘤和非霍奇金淋巴瘤免疫治疗的CD47-SIRPα轴
Pengcheng Zhao1, Longyan Xie2, Lei Yu2
1School of Life Sciences and Medicine, Shandong University of Technology, Zibo, Shandong 255000, China.
Genes & diseases
|August 17, 2023
概括
阻止CD47-SIRPα相互作用,癌细胞利用它来逃避免疫细胞,提供了一个有前途的治疗策略. 本综述详细介绍了针对淋巴瘤治疗这一轴的当前方法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- CD47-SIRPα通路对于免疫平衡至关重要,防止巨细胞攻击健康细胞.
- 癌细胞,特别是淋巴瘤,过度表达CD47,向巨细胞发出"不要吃我"的信号,逃避细胞分裂.
- 针对CD47-SIRPα轴是一个潜在的策略,可以克服各种癌症的免疫逃避.
研究的目的:
- 审查目前针对CD47-SIRPα轴的治疗策略,以治疗淋巴瘤.
- 总结一下在阻止这种免疫检查点方面的临床前和临床进展.
主要方法:
- 对癌症治疗中CD47-SIRPα阻断的科学文献的综述.
- 分析不同的治疗方式,包括抗体,融合蛋白,小分子和.
- 对专注于霍奇金淋巴瘤和非霍奇金淋巴瘤的研究进行审查.
主要成果:
- 目前正在研究针对CD47-SIRPα轴的多种策略.
- 这些策略包括抗体,SIRPα Fc融合蛋白,小分子抑制剂和.
- 有望的临床前和临床数据存在于淋巴瘤治疗.
结论:
- CD47-SIRPα轴的阻塞是淋巴瘤的可行的治疗策略.
- 目前正在进行的研究和临床试验正在评估针对这种途径的各种药物的疗效.
- 需要进一步开发以解决淋巴瘤治疗中未得到满足的临床需求.
相关概念视频
01:27Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K